Search Results - "Meent, Dorien Groenendaal – van de"

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Muscarinic M3 Receptor‐Positive Allosteric Modulator ASP8302 Following Single and Multiple Ascending Oral Doses in Healthy Volunteers by Takusagawa, Shin, Treijtel, Nicoline, Saito, Masako, Michon, Ingrid, Miyatake, Daisuke, Osaki, Fumio, Guro, Sayuri, Fadini, Tomasso, Sekino, Hisakuni, Aarden‐Bakker, Marlous, Kuroishi, Kentaro, Till, Jan Willem Olivier, Groenendaal‐van de Meent, Dorien, Vries, Michiel

“…ASP8302 is an orally administered positive allosteric modulator of the muscarinic M3 receptor. Two Phase 1 studies were conducted, a first‐in‐human study in…”
Get full text

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor by Groenendaal-van de Meent, Dorien, Adel, Martin den, Noukens, Jan, Rijnders, Sanne, Krebs-Brown, Axel, Mateva, Lyudmila, Alexiev, Assen, Schaddelee, Marloes

“…Background and Objective Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor in phase III development for the treatment of anaemia associated…”
Get full text

Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open‐Label, 1‐Sequence, Crossover Studies by Groenendaal‐van de Meent, Dorien, den Adel, Martin, Kerbusch, Virginie, Dijk, Jan, Shibata, Tomohisa, Kato, Kota, Schaddelee, Marloes

“…Roxadustat inhibits breast cancer resistance protein and organic anion transporting polypeptide 1B1, which can affect coadministered statin concentrations…”
Get full text

Pilocarpine‐Induced Effects on Salivary Secretion as a Pharmacological Biomarker for Cholinergic Parasympathetic Activation by Treijtel, Nicoline, Groenendaal‐van de Meent, Dorien, Michon, Ingrid, Korstanje, Cees, Meijer, John, Francke, Klaus, Grossmann, Matthias, Vries, Michiel

“…Pilocarpine‐induced salivary secretion could serve as a nontherapeutic target engagement biomarker in a clinical setting to test the activity of an M3 positive…”
Get full text

An Open‐Label, Single‐Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults by Kato, Kota, den Adel, Martin, Groenendaal‐van de Meent, Dorien, Ohtsu, Yoshiaki, Takada, Akitsugu, Katashima, Masataka

“…Amenamevir is an inhibitor of the helicase‐primase enzyme complex developed for the treatment of varicella zoster virus. This mass balance study investigated…”
Get full text

Population pharmacokinetics of roxadustat in Japanese dialysis‐dependent chronic kidney disease patients with anaemia by Takada, Akitsugu, Shibata, Tomohisa, Shiga, Takanori, Groenendaal‐van de Meent, Dorien, Komatsu, Kanji

“…Aims Our objective was to develop a population pharmacokinetic (PK) model to describe roxadustat plasma concentrations in Japanese dialysis‐dependent chronic…”
Get full text

Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals by Groenendaal-van de Meent, Dorien, Kerbusch, Virginie, Barroso-Fernandez, Begona, den Adel, Martin, van Dijk, Jan, Golor, Georg, Schaddelee, Marloes

“…Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, treats anemia in chronic kidney disease. Hyperphosphatemia, a common complication in…”
Get full text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Muscarinic M 3 Receptor-Positive Allosteric Modulator ASP8302 Following Single and Multiple Ascending Oral Doses in Healthy Volunteers by Takusagawa, Shin, Treijtel, Nicoline, Saito, Masako, Michon, Ingrid, Miyatake, Daisuke, Osaki, Fumio, Guro, Sayuri, Fadini, Tomasso, Sekino, Hisakuni, Aarden-Bakker, Marlous, Kuroishi, Kentaro, van Till, Jan Willem Olivier, Groenendaal-van de Meent, Dorien, de Vries, Michiel

“…ASP8302 is an orally administered positive allosteric modulator of the muscarinic M receptor. Two Phase 1 studies were conducted, a first-in-human study in…”
Get full text

The Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction Study by Groenendaal-van de Meent, Dorien, den Adel, Martin, Rijnders, Sanne, Krebs-Brown, Axel, Kerbusch, Virginie, Golor, Georg, Schaddelee, Marloes

“…Abstract Purpose Roxadustat is a small-molecule hypoxia-inducible factor prolyl-hydroxylase inhibitor in late-stage clinical development for the treatment of…”
Get full text

Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor by Groenendaal-van de Meent, Dorien, Kerbusch, Virginie, Kaspera, Rudiger, Barroso-Fernandez, Begona, Galletti, Piergiorgio, Klein, Gernot K., den Adel, Martin

“…Background and Objectives Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for anemia in chronic kidney disease. The…”
Get full text

Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies by Kusawake, Tomohiro, Keirns, James J., Kowalski, Donna, den Adel, Martin, Groenendaal-van de Meent, Dorien, Takada, Akitsugu, Ohtsu, Yoshiaki, Katashima, Masataka

“…Introduction Amenamevir (ASP2151) is a nonnucleoside antiherpesvirus compound available for the treatment of varicella–zoster virus infections. In this article…”
Get full text

Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects by Groenendaal-van de Meent, Dorien, den Adel, Martin, van Dijk, Jan, Barroso-Fernandez, Begona, El Galta, Rachid, Golor, Georg, Schaddelee, Marloes

“…Background and Objectives Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney…”
Get full text

YM150, An Oral Direct Inhibitor of Factor Xa, Demonstrated a Predictable and Dose-Proportional Pharmacokinetic/Pharmacodynamic Profile After Single and Multiple Dosing: Results From Three Studies by van de Meent, Dorien Groenendaal–, Heeringa, Marten, Kadokura, Takeshi, Verheggen, Frank, Strabach, Gregory, Heinzerling, Hartmut

“…Abstract 3323 YM150 is a potent oral direct factor Xa (FXa) inhibitor that is rapidly and extensively metabolized into YM-222714 after oral administration…”
Get full text

Impact of Renal Impairment and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat: PO2369 by Groenendaal-van de Meent, Dorien, Kerbusch, Virginie, Kaspera, Rudiger, Barroso, Maria B., Galletti, Piergiorgio, Klein, Gernot, den Adel, Martin

Get full text

SO052EFFECT OF SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF ROXADUSTAT, AN ORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR by Groenendaal-van de Meent, Dorien, Kerbusch, Virginie, Kaspera, Rudiger, Barroso-Fernandez, Begona, Galletti, Piergiorgio, Klein, Gernot K, Den Adel, Martin

“…Abstract Background and Aims Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor used at titrated doses to treat anaemia in…”
Get full text

Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults by Kusawake, Tomohiro, den Adel, Martin, Groenendaal-van de Meent, Dorien, Garcia-Hernandez, Alberto, Takada, Akitsugu, Kato, Kota, Ohtsu, Yoshiaki, Katashima, Masataka

“…Introduction Amenamevir is a nonnucleoside antiherpes virus compound available for treating herpes zoster infections. Four studies aimed to determine any…”
Get full text

FP390MODERATE HEPATIC IMPAIRMENT HAS ONLY A MINOR IMPACT ON THE PHARMACOKINETICS OF ROXADUSTAT, AN ORAL HYPOXIA-INDUCIBLE FACTOR PROLYL-HYDROXYLASE INHIBITOR by Groenendaal−van de Meent, Dorien, den Adel, Martin, Noukens, Jan, Rijnders, Sanne, Krebs-Brown, Axel, Mateva, Lyudmila, Alexiev, Assen, Schaddelee, Marloes

Get full text

Co-Administration of YM150, An Oral Direct Factor Xa Inhibitor, and Naproxen Does Not Result In Clinically Relevant Changes to the Pharmacodynamic or Pharmacokinetic Profile of Either Agent by Heeringa, Marten, Garcia-Hernandez, Alberto, Kadokura, Takeshi, Meent, Dorien Groenendaal – van de, Strabach, Gregory, Mol, Roelof, Eltink, Charlotte, Heinzerling, Hartmut

“…Abstract 4393 YM150, a potent oral direct factor Xa (FXa) inhibitor, is in development for the prevention of venous thromboembolism after major surgery and of…”
Get full text